Skip to content

Speakers

Expand/Collapse

William Hastings
Exploratory ImmunoOncology Investigator
Novartis Institute of Biomedical Research

Day One

Wednesday 8th May 2019

1:40 pm | Panel Discussion: Incorporating the Immune Component - Requirements for IO Models When Mimicking the Microenvironment in a Dish

1:10 pm | Using 3D Models to Investigate Mechanisms of Relieving Suppression of TME

Tim Spicer
Senior Associate Director - Scientific & Molecular Medicine
Scripps Institute

Day Two

Thursday 9th May 2019

2:40 pm | Summary Panel Discussion - Assessing Where 3D Systems Shine in Discovery

1:40 pm | KEYNOTE: Combined Genetic Analysis and 3D Screening of Approved Drugs Directly on GBM Patient Tumors

Szczepan Baran
Head of Emerging Technologies
Novartis

Day One

Wednesday 8th May 2019

11:10 am | Panel Discussion: How, When, Where?! Selecting and Choosing the Right 3D System

8:40 am | Beyond 3D-Models - Building Confidence in Microphysiological Models at Novartis

Sylvia Boj
Director - Scientific & Group Leader
Hubrecht Organoid Technology

Day Two

Thursday 9th May 2019

11:40 am | Fireside Chat: Are PDO’s The New PDX?

11:10 am | Patient-Derived Organoids for development and discovery of Oncology and Immuno-Oncology Drugs

Shane Horman
Research Investigator III
Novartis GNF

Day One

Wednesday 8th May 2019

8:30 am | Chair’s Welcoming Remarks

Day Two

Thursday 9th May 2019

2:40 pm | Summary Panel Discussion - Assessing Where 3D Systems Shine in Discovery

2:10 pm | Industrialized 3D Drug Discovery: Spheroids in 1536-well Format

9:00 am | Chair’s Opening Remarks

Roger Kamm
Professor
MIT

WORKSHOP B

May 7, 2019

11:30 am | Designing Cancer-Microfluidic Models: Challenges & Considerations For Primary & Metastatic Tumors

Day One

Wednesday 8th May 2019

1:40 pm | Panel Discussion: Incorporating the Immune Component - Requirements for IO Models When Mimicking the Microenvironment in a Dish

Monica Gostissa
Head of Pharmacology
Jounce Therapeutics

Day One

Wednesday 8th May 2019

1:40 pm | Panel Discussion: Incorporating the Immune Component - Requirements for IO Models When Mimicking the Microenvironment in a Dish

Karsten Boehnke
Oncology TME & Translational Research
Eli Lilly and Company

Day Two

Thursday 9th May 2019

11:40 am | Fireside Chat: Are PDO’s The New PDX?

9:10 am | Application of Patient-Derived Organoid Cultures as Preclinical Model Systems for Target Validation & Translational Research

Jeffrey T. Borenstein
Group Leader, Synthetic Biology & Bio Instrumentation
Draper

Day One

Wednesday 8th May 2019

11:40 am | A Microfluidic Platform for Rapid and Predictive Assessment of Immune Checkpoint Inhibitor Efficacy in Mouse and Human Tumors

Joe Grosso
Senior Lead, Early Clinical
BMS

Elad Katz
Lead Biologist
University of Dundee

WORKSHOP A

May 7, 2019

8:00 am | A Simple Introduction To The Confusing World Of 3D Oncology Models

Dik Van Gent
Professor
Erasmus MC

WORKSHOP B

May 7, 2019

11:30 am | Designing Cancer-Microfluidic Models: Challenges & Considerations For Primary & Metastatic Tumors

Daniel Harrington
Assistant Professor
The University of Texas Health Science Center

WORKSHOP C

May 7, 2019

3:00 pm | 3D Tumour Engineering to Recapitulate Microenvironment

Felipe de Sousa e Melo
Scientist
Genentech

Anita Seshire
Head of Laboratory Cellular Pharmacology & Translational Innovation Platform Oncology
EMD Serono

Day One

Wednesday 8th May 2019

9:10 am | Utilizing Multicellular 3D Models for Preclinical Drug Discovery

Alejandro Amador
Head, Scientific Leader Discovery Biology Automation
GSK

Day Two

Thursday 9th May 2019

2:40 pm | Summary Panel Discussion - Assessing Where 3D Systems Shine in Discovery

1:10 pm | Active-Learning Strategies for High Content Screening to Improve Clinical Relevance of Oncology Therapeutics

Melanie Matheu
CEO, Founder
Prellis Biologics

Day Two

Thursday 9th May 2019

10:55 am | Laser Printed 3D Tissues for Oncology Studies

Audrey Bergeron
Applications Scientist
Corning Life Sciences

Day Two

Thursday 9th May 2019

9:40 am | 3D Technologies for Advanced Cancer Models

Andrew Mearns Spragg
Founder & CSO
Jellagen

Day One

Wednesday 8th May 2019

3:10 pm | Jellagen®: A Next Generation Jellyfish Collagen Matrix Offering New Opportunities for 3D Cell Culture

Brian Wamhoff
Co-founder and Head of Innovation
HemoShear Therapeutics

Mark Paris
Director, Translational Applications
Mitra Biotech

Day One

Wednesday 8th May 2019

10:40 am | KEYNOTE: Transforming Translational Research: CANscript™ - A Better Predictive Model for Oncology

11:10 am | Panel Discussion: How, When, Where?! Selecting and Choosing the Right 3D System